The Long Run with Luke Timmerman

Timmerman Report
undefined
Sep 6, 2023 • 1h 10min

Ep143: Zach Weinberg and Alexis Borisy on Freeing the Biotech Founders

Explore the journey of Curie.Bio founders Zach Weinberg and Alexis Borisy in empowering biotech entrepreneurs. Learn about the hands-on support offered to founders, the evolution of Flatiron Health, and the collaborative approach of Curie Bio in prioritizing founder ownership and control in the biotech industry.
undefined
Aug 24, 2023 • 56min

Ep142: Fred Appelbaum on how 'Living Medicine' Came to Be

Fred Appelbaum, a physician, scientist and leader at the Fred Hutchinson Cancer Center, on 'Living Medicine,' his new book about the development of bone marrow transplantation and the rise of cell therapy.
undefined
Aug 8, 2023 • 1h 10min

Ep141: Colin Hill on Digging Deep into Data, Finding New Drug Targets

Colin Hill, co-founder and CEO of Aitia, on digging deep into biological datasets and finding new drug targets.
undefined
Jul 24, 2023 • 1h 3min

Ep140: Yung Lie on Supporting Young Scientists with Bold, Brave Ideas

Yung Lie, president and CEO of Damon Runyon Cancer Research Foundation, on advancing cancer research by supporting young scientists with bold and brave ideas.
undefined
Jul 10, 2023 • 1h 8min

Ep139: Kevin Conroy on Early Detection of Cancer

Kevin Conroy, CEO of Exact Sciences, on early detection of cancer.
undefined
Jun 27, 2023 • 1h

Ep138: Jodie Morrison on Becoming a Biotech CEO

Jodie Morrison, acting CEO of Q32Bio, on becoming a biotech CEO.
undefined
Jun 14, 2023 • 57min

Ep137: Aaron Ring on Immunotherapy for Cancer & More

Aaron Ring, a scientist at Yale moving to the Fred Hutchinson Cancer Center, on applying immunology and protein engineering for cancer therapy and more.
undefined
May 30, 2023 • 53min

Ep136: Deborah Palestrant on Building Biotech Startups

Deborah Palestrant, partner at 5AM Ventures and head of the 4:59 initiative, on building biotech startups.
undefined
May 8, 2023 • 1h 4min

Ep135: John Maraganore on Developing a New Class of Medicines

John Maraganore, former founding CEO of Alnylam Pharmaceuticals, on his life in biotech and developing RNA interference as a new class of medicine.
undefined
Apr 24, 2023 • 1h 16min

Ep134: Emile Nuwaysir on In Vivo Gene Editing Therapies

Emile Nuwaysir, CEO of Boston-based Ensoma, on developing off-the-shelf in vivo gene editing therapies.

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app